Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
Summary
The FDA has ordered makers of Ozempic, Wegovy, Mounjaro and Zepbound to add warnings about NAION, a rare condition that can cause sudden, sometimes permanent vision loss. The agency says its review found an increased risk among people taking the drugs, but it is not known whether the drugs cause the condition.Key Facts
- NAION occurs when blood flow to the optic nerve is blocked.
- The condition can cause painless vision loss in one eye, which may be permanent.
- The FDA reviewed reports from GLP-1 users and other studies before requiring the warnings.
- The FDA said researchers do not know why people taking GLP-1 drugs may face a higher risk.
- The American Academy of Ophthalmology said any added risk appears small and a causal link has not been established.
- The academy advised patients not to stop their medication without speaking to a doctor and to seek prompt eye care for sudden, painless vision loss.
- Novo Nordisk said the available data do not establish that its medicines cause NAION.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
